BioReference Labs Develops NextGen Sequencing for Dilated Cardiomyopathy Testing


April 10, 2009

April 20, 2009 - BioReference Laboratories Inc. is now offering next- generation sequencing testing for Dilated Cardiomyopathy (DCM) through its GeneDx laboratory.

GeneDx is reportedly the first commercial laboratory in the country, and possibly the world, to offer clinical testing based on next-generation sequencing, full genome sequencing provided through high-speed, high throughput computer-based analysis. GeneDx has designed software said to provide focused, multi-gene diagnostic analysis of complex cases spanning multiple genes. GeneDx first pioneered the use of this platform with its test for Hypertrophic Cardiomyopathy (HCM), which it began offering in September 2008.

It is estimated that 20 to 40 percent of patients diagnosed with idiopathic cardiomyopathy may have a genetic etiology to their condition. The new GeneDx DCM test will allow cardiologists to identify patients with a genetic basis to their dilated cardiac condition. GeneDx provides testing for more than 250 rare disease conditions based on over 200 genes utilizing traditional DNA sequencing.

For more information: